[go: up one dir, main page]

SV2018005729A - Biomarcadores de copanlisib - Google Patents

Biomarcadores de copanlisib

Info

Publication number
SV2018005729A
SV2018005729A SV2018005729A SV2018005729A SV2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A SV 2018005729 A SV2018005729 A SV 2018005729A
Authority
SV
El Salvador
Prior art keywords
respond
patients
progress
biomarkers
nhl
Prior art date
Application number
SV2018005729A
Other languages
English (en)
Inventor
Carol Pena
Li Liu
Jie Cheng
Karl Köchert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2018005729A publication Critical patent/SV2018005729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCIÓN PROPORCIONA BIOMARCADORES BASADOS EN EL PERFIL DE EXPRESIÓN GÉNICA QUE PUEDE DISTINGUIRSE ENTRE PACIENTES QUE RESPONDEN Y/O TIENEN UNA MAYOR SUPERVIVENCIA LIBRE DE PROGRESIÓN Y PACIENTES QUE NO RESPONDEN Y/O TIENEN MENOR SUPERVIVENCIA LIBRE DE PROGRESIÓN A PARTIR DEL TRATAMIENTO CON COPANLISIB EN LINFOMA, QUE INCLUYE NHL INDOLENTE Y AGRESIVO Y CLL. LA PRESENTE INVENCIÓN SE REFIERE AL USO DE GENES DE BCR, PI3K, NFKB, IL6, PROCESOS INFLAMATORIOS Y ESTROMALES COMO BIOMARCADORES PREDICTIVOS PARA DIVERSOS CÁNCERES HUMANOS QUE INCLUYEN, ENTRE OTROS, NHL
SV2018005729A 2016-02-01 2018-08-07 Biomarcadores de copanlisib SV2018005729A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662289715P 2016-02-01 2016-02-01

Publications (1)

Publication Number Publication Date
SV2018005729A true SV2018005729A (es) 2018-12-05

Family

ID=57984907

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005729A SV2018005729A (es) 2016-02-01 2018-08-07 Biomarcadores de copanlisib

Country Status (16)

Country Link
US (1) US20190382839A1 (es)
EP (1) EP3411498A1 (es)
JP (1) JP2019512003A (es)
KR (1) KR20180104129A (es)
CN (1) CN109072307A (es)
AU (1) AU2017215096A1 (es)
BR (1) BR112018015783A2 (es)
CA (1) CA3012951A1 (es)
CL (1) CL2018002070A1 (es)
MA (1) MA43958A (es)
MX (1) MX2018009367A (es)
PH (1) PH12018501622A1 (es)
SG (2) SG10202007322PA (es)
SV (1) SV2018005729A (es)
TN (1) TN2018000272A1 (es)
WO (1) WO2017134030A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
PE20200958A1 (es) * 2017-09-08 2020-09-24 Bayer Consumer Care Ag Solido liofilizado de copanlisib
EP3498266A1 (en) * 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO2005010213A2 (en) * 2003-07-17 2005-02-03 Pacific Edge Biotechnology, Ltd. Markers for detection of gastric cancer
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
UA119537C2 (uk) * 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
TW201819923A (zh) * 2013-06-20 2018-06-01 日商大鵬藥品工業股份有限公司 基於ＰＨＬＤＡ１或ＰＩＫ３Ｃ２Ｂ表現之ＰＩＫ３／ＡＫＴ／ｍＴＯＲ抑制劑之治療效果的預測方法
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
KR20180104129A (ko) 2018-09-19
MA43958A (fr) 2018-12-12
CL2018002070A1 (es) 2018-11-16
TN2018000272A1 (en) 2020-01-16
CA3012951A1 (en) 2017-08-10
AU2017215096A1 (en) 2018-08-09
JP2019512003A (ja) 2019-05-09
WO2017134030A1 (en) 2017-08-10
EP3411498A1 (en) 2018-12-12
SG11201806512VA (en) 2018-08-30
SG10202007322PA (en) 2020-09-29
CN109072307A (zh) 2018-12-21
BR112018015783A2 (pt) 2018-12-26
US20190382839A1 (en) 2019-12-19
PH12018501622A1 (en) 2019-06-03
MX2018009367A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
SV2018005729A (es) Biomarcadores de copanlisib
SV2018005730A (es) Biomarcadores para copanlisib
GT201700033A (es) Anticuerpos anti tigit
TWD190248S (zh) 通氣管
AR095233A1 (es) Métodos y composiciones para el control de malezas
TWD185242S (zh) 集成的通用串行總線裝置延長線
MX2016011538A (es) Acidos nucleicos antisentido.
TWD191254S (zh) 槓鈴護套
MX381263B (es) Artículo absorbente con capa elevada de la lámina delantera en contacto con la piel.
GT201500249A (es) Terapia de combinación
TWD189563S (zh) 鼻管組件
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CY1120084T1 (el) Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων
CL2016002779A1 (es) Composición para el cuidado de la piel
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
CL2016002797A1 (es) Plantilla para formar el contorno de una ceja, provista con un medio de depilacion, un soporte plano flexible que presenta un borde que sigue la progresion del contorno que debe ser formado para la ceja, un area de depilacion situada adyacente a dicho borde del soporte, revestida con un medio de depilacion, y con ayuda optica de posicionamiento sobre al menos una mitad lateral de la plantilla
MX377221B (es) Un uso in vitro de microarns y combinaciones de los mismos para el diagnostico de la enfermedad valvular cronica en canidos.
AR101582A1 (es) Tratamiento de tejido mamario con óxido nítrico
AR120118A2 (es) Anticuerpos anti tigit
TWD180830S (zh) 汽車安全座椅
TWD188797S (zh) Seat
TWD186713S (zh) 拖鞋之部分
TWD167852S (zh) 蕾絲邊布料
TWD186709S (zh) 拖鞋之部分